Literature DB >> 21371927

Early-onset growth hormone deficiency results in diastolic dysfunction in adult-life and is prevented by growth hormone supplementation.

L Groban1, M Lin, K A Kassik, R L Ingram, W E Sonntag.   

Abstract

OBJECTIVE: The primary goal of growth hormone (GH) replacement is to promote linear growth in children with growth hormone deficiency (GHD). GH and insulin-like growth factor-1 (IGF-1) are also known to have roles in cardiac development and as modulators of myocardial structure and function in the adult heart. However, little is known about cardiac diastolic function in young adults with childhood onset GH deficiency in which GH treatment was discontinued following puberty. The aim of the study was to evaluate the effects of long standing GHD and peri-pubertal or continuous GH replacement therapy on diastolic function in the adult dwarf rat.
DESIGN: The dwarf rat, which possesses a mutation in a transcription factor necessary for development of the somatotroph, does not exhibit the normal peri-pubertal rise in GH around day 28 and was used to model childhood or early-onset GHD (EOGHD). In another group of male dwarfs, GH replacement therapy was initiated at 4 weeks of age when GH pulsatility normally begins. Ten weeks after initiation of injections, GH-treated dwarf rats were divided into 2 groups; continued treatment with GH for 12 weeks (GH-replete) or treatment with saline for 12 weeks. This latter group models GH supplementation during adolescence with GHD beginning in adulthood (adult-onset GHD; AOGHD). Saline-treated heterozygous (HZ) rats were used as age-matched controls. At 26 weeks of age, cardiac function was assessed using invasive or noninvasive (conventional and tissue Doppler) indices of myocardial contractility and lusitropy.
RESULTS: Systolic function, as determined by echocardiography, was similar among groups. Compared with HZ rats and GH-replete dwarfs, the EOGHD group exhibited significant reductions in myocardial relaxation and increases in left ventricular filling pressure, indicative of moderate diastolic dysfunction. This was further associated with a decrease in the cardiac content of sarcoplasmic reticulum Ca(2+) ATPase (SERCA2), one of the important cardiac calcium regulatory proteins. Dwarfs supplemented with GH during the peri-adolescence stage, but not beyond (AOGHD), exhibited a subtle prolongation in the deceleration time to early filling. In contrast, continual GH replacement preserved diastolic function such that the cardiac phenotype of the GH-replete dwarfs resembled that of their age-matched HZ counterpart. DISCUSSION: Our data indicate that GHD during adolescence leads to overt diastolic dysfunction in early adulthood and this is prevented by continual GH replacement therapy. Since discontinuation of GH replacement following adolescence only mitigated the lusitropic deficits that were observed in untreated dwarfs, GH treatment into adulthood could be beneficial.
Copyright © 2011 Growth Hormone Research Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371927      PMCID: PMC3085723          DOI: 10.1016/j.ghir.2011.01.003

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  61 in total

1.  Cardiac effects of low-dose growth hormone replacement therapy in growth hormone-deficient adults. An 18-month randomised, placebo-controlled, double-blind study.

Authors:  Simone B Sneppen; Frank Steensgaard-Hansen; Ulla Feldt-Rasmussen
Journal:  Horm Res       Date:  2002

2.  The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study.

Authors:  Annamaria Colao; Carolina di Somma; Rosario Pivonello; Alberto Cuocolo; Letizia Spinelli; Domenico Bonaduce; Marco Salvatore; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

Review 3.  Models of growth hormone and IGF-1 deficiency: applications to studies of aging processes and life-span determination.

Authors:  Christy S Carter; Melinda M Ramsey; Rhonda L Ingram; Adrienne B Cashion; William T Cefalu; Z Q Wang; William E Sonntag
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2002-05       Impact factor: 6.053

4.  Echocardiographic assessment of cardiac morphology and function in mutant dwarf rats.

Authors:  S Longobardi; A Cittadini; H Strömer; S E Katz; J D Grossman; R G Clark; J P Morgan; P S Douglas
Journal:  Growth Horm IGF Res       Date:  2000-10       Impact factor: 2.372

5.  Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study.

Authors:  D W Kitzman; J M Gardin; J S Gottdiener; A Arnold; R Boineau; G Aurigemma; E K Marino; M Lyles; M Cushman; P L Enright
Journal:  Am J Cardiol       Date:  2001-02-15       Impact factor: 2.778

6.  The cardiovascular risk of GH-deficient adolescents.

Authors:  Annamaria Colao; Carolina Di Somma; Mariacarolina Salerno; Letizia Spinelli; Francesco Orio; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

Review 7.  Tissue Doppler imaging a new prognosticator for cardiovascular diseases.

Authors:  Cheuk-Man Yu; John E Sanderson; Thomas H Marwick; Jae K Oh
Journal:  J Am Coll Cardiol       Date:  2007-04-30       Impact factor: 24.094

8.  Circulating levels of insulin-like growth factor-1 and its binding proteins in patients with hypertrophic cardiomyopathy.

Authors:  Hideyuki Saeki; Mareomi Hamada; Kunio Hiwada
Journal:  Circ J       Date:  2002-07       Impact factor: 2.993

9.  Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults.

Authors:  S Ezzat; S Fear; R-C Gaillard; C Gayle; H Landy; S Marcovitz; T Mattioni; S Nussey; A Rees; E Svanberg
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

Review 10.  Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system.

Authors:  Amir S Khan; David C Sane; Thomas Wannenburg; William E Sonntag
Journal:  Cardiovasc Res       Date:  2002-04       Impact factor: 10.787

View more
  4 in total

Review 1.  The emerging role of IGF-1 deficiency in cardiovascular aging: recent advances.

Authors:  Zoltan Ungvari; Anna Csiszar
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-26       Impact factor: 6.053

2.  Low bone mineral density in a growth hormone deficient (GHD) adolescent.

Authors:  Anna Capozzi; Silvia Della Casa; Barbara Altieri; Alfredo Pontecorvi
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

Review 3.  Possible effects of an early diagnosis and treatment in patients with growth hormone deficiency: the state of art.

Authors:  Stefano Stagi; Perla Scalini; Giovanni Farello; Alberto Verrotti
Journal:  Ital J Pediatr       Date:  2017-09-16       Impact factor: 2.638

4.  Effect of recombinant human growth hormone therapy on blood lipid and carotid intima-media thickness in children with growth hormone deficiency.

Authors:  Ming Chen; Dongmei Gan; Yili Luo; Sharvan Rampersad; Lu Xu; Shaoling Yang; Nan Li; Hong Li
Journal:  Pediatr Res       Date:  2018-01-17       Impact factor: 3.756

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.